Cargando…
Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling
The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166238/ https://www.ncbi.nlm.nih.gov/pubmed/37389094 http://dx.doi.org/10.5415/apallergy.0000000000000020 |
_version_ | 1785038402575400960 |
---|---|
author | Mak, Hugo W.F. Chan, Elsie T.S. Yim, Jackie S.H. Lee, Elaine Lam, Dorothy L.Y. Chiang, Valerie Li, Philip H. |
author_facet | Mak, Hugo W.F. Chan, Elsie T.S. Yim, Jackie S.H. Lee, Elaine Lam, Dorothy L.Y. Chiang, Valerie Li, Philip H. |
author_sort | Mak, Hugo W.F. |
collection | PubMed |
description | The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of life (HRQoL) remains poorly known. OBJECTIVE: The study objective is to translate and validate a Chinese version of DrHy-Q and investigate the effect of PA delabeling on HRQoL using DrHy-Q. METHODS: A Chinese DrHy-Q was translated then completed by patients with drug allergy labels for psychometric validation. Afterwards, another cohort of patients finished the Chinese DrHy-Q before and after their PA workup for pre–post comparison. RESULTS: A total of 130 patients were studied. Sixty-three patients (79.4% female; median age = 59 ± 15 years) completed the Chinese DrHy-Q for validation (mean score = 38.9 ± 23.5). It demonstrated excellent internal consistency (Cronbach α = 0.956; 95% confidence interval [CI], 0.939–0.971) and test–retest reliability (intraclass correlation coefficient = 0.993 [95% CI, 0.969–0.998]). Construct validity was confirmed by its one-dimensional structure in factor analysis. Divergent validity was established because only 2 (out of 9) SF-36 scales showed weak negative correlations to DrHy-Q. Patients with multiple implicated drugs presented significantly higher DrHy-Q scores than those with only a single drug (42.0 ± 22.5 vs 28.7 ± 24.4; P = 0.038), showing discriminant validity. Subsequently, another 67 patients (73.1% female; median age = 56 ± 15 years) underwent PA investigations and completed their pre–post DrHy-Q. A significant drop in DrHy-Q score was shown (40.8 ± 21.7 vs 26.6 ± 22.5; Cohen’s d = 0.964; P < 0.001), reflecting improvement in HRQoL. CONCLUSION: The Chinese DrHy-Q is reliable and valid for HRQoL assessment. PA delabeling significantly benefits patients’ HRQoL. Future larger-scale studies are warranted to corroborate our findings. |
format | Online Article Text |
id | pubmed-10166238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101662382023-06-29 Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling Mak, Hugo W.F. Chan, Elsie T.S. Yim, Jackie S.H. Lee, Elaine Lam, Dorothy L.Y. Chiang, Valerie Li, Philip H. Asia Pac Allergy Original Article The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of life (HRQoL) remains poorly known. OBJECTIVE: The study objective is to translate and validate a Chinese version of DrHy-Q and investigate the effect of PA delabeling on HRQoL using DrHy-Q. METHODS: A Chinese DrHy-Q was translated then completed by patients with drug allergy labels for psychometric validation. Afterwards, another cohort of patients finished the Chinese DrHy-Q before and after their PA workup for pre–post comparison. RESULTS: A total of 130 patients were studied. Sixty-three patients (79.4% female; median age = 59 ± 15 years) completed the Chinese DrHy-Q for validation (mean score = 38.9 ± 23.5). It demonstrated excellent internal consistency (Cronbach α = 0.956; 95% confidence interval [CI], 0.939–0.971) and test–retest reliability (intraclass correlation coefficient = 0.993 [95% CI, 0.969–0.998]). Construct validity was confirmed by its one-dimensional structure in factor analysis. Divergent validity was established because only 2 (out of 9) SF-36 scales showed weak negative correlations to DrHy-Q. Patients with multiple implicated drugs presented significantly higher DrHy-Q scores than those with only a single drug (42.0 ± 22.5 vs 28.7 ± 24.4; P = 0.038), showing discriminant validity. Subsequently, another 67 patients (73.1% female; median age = 56 ± 15 years) underwent PA investigations and completed their pre–post DrHy-Q. A significant drop in DrHy-Q score was shown (40.8 ± 21.7 vs 26.6 ± 22.5; Cohen’s d = 0.964; P < 0.001), reflecting improvement in HRQoL. CONCLUSION: The Chinese DrHy-Q is reliable and valid for HRQoL assessment. PA delabeling significantly benefits patients’ HRQoL. Future larger-scale studies are warranted to corroborate our findings. Lippincott Williams & Wilkins 2023-04-28 2023-03 /pmc/articles/PMC10166238/ /pubmed/37389094 http://dx.doi.org/10.5415/apallergy.0000000000000020 Text en Copyright © 2023. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Article Mak, Hugo W.F. Chan, Elsie T.S. Yim, Jackie S.H. Lee, Elaine Lam, Dorothy L.Y. Chiang, Valerie Li, Philip H. Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling |
title | Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling |
title_full | Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling |
title_fullStr | Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling |
title_full_unstemmed | Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling |
title_short | Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling |
title_sort | validation of the chinese drug hypersensitivity quality of life questionnaire: role of delabeling |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166238/ https://www.ncbi.nlm.nih.gov/pubmed/37389094 http://dx.doi.org/10.5415/apallergy.0000000000000020 |
work_keys_str_mv | AT makhugowf validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling AT chanelsiets validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling AT yimjackiesh validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling AT leeelaine validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling AT lamdorothyly validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling AT chiangvalerie validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling AT liphiliph validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling |